Australia's most trusted
source of pharma news
Friday, 10 April 2026
Posted 10 April 2026 AM
The TGA accepted five drug applications for review in February, including new indications for two big products and three innovative medicines.
Among the updated list is a new indication for AstraZeneca’s antibody-drug conjugate Datroway – one of the company’s blockbuster hopefuls to deliver on its US$80 billion revenue target by the end of the decade.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.